Pipeline Overview

Candidate
Lead Optimization
IND-Enabling
Phase 1
Phase 2
Phase 3

Clinical Program

RBN-2397
PARP7 Inhibitor
Status: Phase: 1

Preclinical Programs

monoPARP Inhibitor
Status: IND-Enabling Studies
NADase Inhibitor
Status: Lead Optimization

Discovery Programs

Using our proprietary BEACON+ platform, we have identified eight additional NAD+-utilizing enzyme targets to date that are in various stages of discovery from target validation to hit identification

Join our team of experts.
Find Out More